AIM
CRSP icon

Assured Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Assured Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,862
Closed -$109K – 1188
2018
Q2 		$109K Sell
1,862
-1,613
-46% -$91.9K ﹤0.01% 1071
2018
Q1 		$159K Buy
+3,475
New +$143K ﹤0.01% 1012

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Assured Investment Management's CRSP Position: Q3 2018 in Review

Assured Investment Management sold out of CRISPR Therapeutics (CRSP) in Q3 2018, closing a stake of 1,862 shares — an estimated $109K sold.

Assured Investment Management first reported a position in CRSP in Q1 2018 and held it in 2 quarters. The position peaked at $159K in Q1 2018. 179 funds tracked by Wall St. Rank hold CRSP as of Q3 2018.

  • Assured Investment Management reported no remaining CRISPR Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Assured Investment Management sold 1,862 CRISPR Therapeutics shares in Q3 2018, an estimated $109K.
  • Assured Investment Management first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 2 quarters.
  • Assured Investment Management's CRISPR Therapeutics position peaked at $159K in Q1 2018.
  • 179 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2018.

Based on Assured Investment Management's 13F filing for Q3 2018, filed 14 Nov 2018.